Chelsea Therapeutics International Ltd. (CHTP)
Chelsea Therapeutics Receives Complete Response Letter from Food and Drug Administration for Northera(TM) (droxidopa) Capsules Call
March 29, 2012 08:00 am ET
Kate McNeil - Director, IR
Dr. Simon Pedder - President & CEO
Bill Schwieterman - CMO
Nick Riehle - VP, Administration and CFO
Keith Schmidt - VP, Marketing and Sales
Robyn Karnauskas - Deutsche Bank
Juan Sanchez - Ladenburg
Jonathon Eckard - Leerink Swann
Scott Henry - Roth Capital
Liana Moussatos - Wedbush Securities
Good day ladies and gentlemen and an welcome to the Chelsea Therapeutics March 29th conference call. At this time all participant lines are in a listen-only mode. Later we will conduct the question-and-answer session and instructions will be given at that time. (Operator Instructions). As a reminder this conference is being recorded. I would now like to turn the conference over to your host, Ms. Kate McNeil, please go ahead.
Thank you, operator. Good morning and thank you all for joining us to discuss our Northera new drug application for the treatment of symptomatic neurogenic orthostatic hypotension and the complete response letter received yesterday from the US Food and Drug Administration. Our press release regarding the FDA’s decision can be found on our website www.chelseatherapeutics.com. Joining me from Chelsea is Dr. Simon Pedder, President and Chief Executive Officer; Chief Financial Officer Mr. Nick Riehle; Chief Medical Officer Dr. Bill Schwieterman; Chief Scientific Officer Arthur Hewitt; VP of marketing and sales Mr. Keith Schmidt; and our Chief Operating Officer, Joe Oliveto.